Zymeworks (Zymeworks) GF Value : $14.38 (As of Apr. 27, 2024)

View and export this data going back to 2017. Start your Free Trial

What is Zymeworks GF Value?

The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:

Historical multiples (PE Ratio, PS Ratio, PB Ratio and Price-to-Free-Cash-Flow) that the stock has traded at.
GuruFocus adjustment factor based on the company’s past returns and growth.
Future estimates of the business performance.

We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.

Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

As of today (2024-04-27), Zymeworks's share price is $8.26. Zymeworks's GF Value is $14.38. Therefore, Zymeworks's Price-to-GF-Value for today is 0.57.

Based on the relationship between the current stock price and the GF Value, GuruFocus believes Zymeworks is Possible Value Trap, Think Twice.

Zymeworks (NAS:ZYME) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

Posssible Evaluations	All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)	Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) There is only a sufficient margin of safety when the stock is undervalued.

Zymeworks's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	8.26	/	14.38
	=	0.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zymeworks GF Value Related Terms

Thank you for viewing the detailed overview of Zymeworks's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Zymeworks (Zymeworks) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zymeworks Inc (NAS:ZYME) » Definitions » GF Value

Comparable Companies

Traded in Other Exchanges

ZA8:Germany

Address

108 Patriot Drive, Suite A, Middletown, DE, USA, 19709

Website

https://www.zymeworks.com

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Executives

Paul Andrew Moore	officer: Chief Scientific Officer	114 EAST 4TH AVENUE, SUITE 800, VANCOUVER A1 V5T 1G4
Christopher Astle	officer: SVP & Chief Financial Officer	114 EAST 4TH AVENUE, SUITE 800, VANCOUVER A1 V5T 1G4
Kenneth Galbraith	director, officer: Chair & CEO	OCEAN PARK RPO PO BOX 45025, 12851 16TH AVE, SURREY A1 V4A9L1
Carlos Campoy	director	11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011
Ecor1 Capital, Llc	10 percent owner	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Miller Derek John Michael	director	108 PATRIOT DRIVE, SUITE A, 1385 WEST 8TH AVENUE, SUITE 540, MIDDLETOWN DE 19709
Neil A Klompas	officer: President & COO	114 EAST 4TH AVENUE, SUITE 800, VANCOUVER A1 V5T 1G4
Lota S. Zoth	director	334 CR 692, BUFFALO GAP TX 79508
Troy Cox	director	C/O FOUNDATION MEDICINE, INC., C/O FOUNDATION MEDICINE, INC., 150 SECON, CAMBRIDGE MA 02141
Kenneth J. Hillan	director	C/O ACHAOGEN, INC., 7000 SHORELINE COURT, SUITE 371, SOUTH SAN FRANCISCO CA 94080
Hollings Renton	director
Kelvin Neu	director	860 WASHINGTON STREET, 10TH FLOOR, NEW YORK NY 10014
Natalie Sacks	director	C/O ADURO BIOTECH, INC., 740 HEINZ AVENUE, BERKELEY CA 94710
Susan Mahony	director	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Neil Josephson	officer: Chief Medical Officer	114 EAST 4TH AVENUE, SUITE 800, VANCOUVER A1 V5T 1G4